test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/21647


Title: Eptifibatide: In the treatment of acute coronary syndromes
Authors: Oak, M. A.
Rege, N. N.
Issue Date: 31-Dec-2000
Publisher: Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
Citation: Journal of Postgraduate Medicine (ISSN: 0972-2823) Vol 46 Num 2
Abstract: Formation of a platelet rich white thrombus due to disruption of coronary vascular endothelium is the crucial event in progression of stable angina to acute coronary syndrome (ACS) and complications of percutaneous coronary interventions (PCI). Atherosclerotic plaque rupture, vascular injury (e.g., from PCI procedures), or denudation of endothelium exposes the subendothelial matrix of the vessel to circulating platelets. Subsequent activation of platelets results in a conformational change in the Glycoprotein (GP) IIb/IIIa present in the platelet membrane thereby activating it's receptor function for fibrinogen and Von Willebrand factor in the plasma. Fibrinogen and Von Willebrand factor link the GP IIb/IIIa from the adjacent platelets leading to their aggregation and thus thrombus formation. This binding of fibrinogen and Von Willebrand factor to the platelet membrane glycoprotein IIb/ IIIa receptor is the final common pathway by which the activated platelets aggregate to form a platelet rich white thrombus irrespective of initial activating stimulus. Eptifibatide blocks this final common pathway and has been approved as a new drug for ACS by The Drug Controller General of India in August 1999.
URI: http://hdl.handle.net/1807/21647
Other Identifiers: http://www.bioline.org.br/abstract?id=jp00042
Rights: Copyright 2000 Journal of Postgraduate Medicine. Online full text also at http://www.jpgmonline.com
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
jp00042.html13.49 kBHTMLView/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft